Orthocell Ltd (ASX: OCC) shares are down more than 35% over the past year, but the analysts at Bell Potter believe a recovery is on the cards.

They have a bullish share price target on the company, which I’ll get to shortly.

Biotech focused on bone and soft tissue repair

So what does the company actually do?

In their own words:

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications.

Now let’s look at the company’s recent full-year results release.

Orthocell generated $13.2 million in revenue for FY26, up 45%, but its net loss also increased, jumping 59% to $13.6 million.

Chief Executive Officer Paul Anderson said:

FY26 was an important step in Orthocell’s evolution as a global regenerative medicine company, with record revenue and continued progress across established markets and selected international opportunities. We delivered record revenue of $13.2 million, up 45% on FY25, including a record June quarter of $3.8 million. Remplir and Striate were the principal drivers, supported by continued strength in Australia and growing contributions from the United States and other international markets.

Mr Anderson said Australia was the company’s most established market and was expected to continue growing, while FY26 was the first full year of Remplir’s availability in the US.

He said further re the US market:

We are very pleased with this first-year progress, while recognising that the path from surgeon interest to hospital approval, first use and repeat ordering can extend over several months. In FY27, our priority is to deepen adoption within the established footprint by investing in targeted sales, education and marketing initiatives that support distributors and surgeons as Remplir becomes part of routine clinical practice and repeat use grows.

Shares looking cheap according to broker

Bell Potter said in its note to clients that the US would be the market to watch.

They said:

US access expanded strongly in FY26, but revenue has yet to scale in line with the footprint. The key watchpoint now shifts to repeat utilisation and revenue conversion, which management has highlighted as a core FY27 priority. This is consistent with our prior view and leaves the broader thesis intact. We maintain our Buy (speculative) rating and reduce valuation to $1.13 from $1.19 following earnings adjustments.

Orthocell shares are currently changing hands for 72.5 cents. The company is valued at $196.1 million.

The post Bell Potter says this ASX biotech could rise 56% appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: South32, Australian Finance Group, Magellan shares
• This ASX lithium project developer could rise more than 300%: Broker
• Top 3 ASX 200 shares that lifted their dividend this reporting season
• Xero shares jump 33% from a 7-year low: Buy, sell or hold?
• Warning: Corporate Travel shares have crashed 80%. What on earth just happened?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are up 0.4% to 9,014.6 points on Thursday.

Let’s check out some new ratings on ASX shares today.  

Magellan Financial Group Ltd (ASX: MFG)

The Magellan Financial Group share price is $8.54, up 2.8% today and down 19% over 12 months. 

Morgans has an accumulate rating on this ASX 200 financial share after Magellan’s FY26 results.

The broker said: 

MFG’s group operating profit after tax (A$145m) was down 9% on the pcp (A$159m) and 2% above consensus (A$142m).

Guidance was the main factor weighing on the result, with management flagging numerous headwinds for FY27 — which shapes up as a consolidation year — alongside signs of a slowdown in Barrenjoey growth in 2H26 (despite otherwise impressive overall numbers).

Our price target falls from A$11.26 to A$10.25. While MFG faces some near-term pressures, we continue to believe the company is well positioned to drive medium-term growth.

South32 Ltd (ASX: S32)

The South32 share price is $5.19, up 0.7% today and up 97% over 12 months.

Morgans downgraded this ASX 200 mining share from accumulate to hold after South32’s FY26 report.

The broker said:

With S32’s share price outperforming even its pure-copper ASX peers year-to-date on larger cycle leverage, we downgrade our rating to HOLD (from Accumulate).

S32 delivered a broadly in line FY26 result, with FY27 guidance on unit cost and capex reflecting existing market expectations of continued cost pressure.

Don’t count on S32 returning a meaningful part of the Alcoa deal proceeds, with the company going as far as talking down its commitment to its ordinary dividend.

Similar to some of its peers, S32’s earnings have enjoyed a healthy upcycle, our concern is that it is starting to increasingly look factored in (while the company arguably swaps its earnings clout for a mid-cycle M&A war chest post Alcoa deal).

Australian Finance Group Ltd (ASX: AFG)

The Australian Finance Group share price is $1.52, up 2.2% today and down 43% over 12 months. 

Jonathan Tacadena from MPC Markets has a sell rating on this S&P/ASX 300 Index (ASX: XKO) financial share. 

On The Bull this week, Tacadena said:  

This mortgage broking group reported net profit after tax of $49 million in full year 2026, up 39 per cent on the prior corresponding period.

AFG grew its network to more than 4300 brokers. While profit growth looks good on paper, the company faces a difficult operating backdrop, in our view.

Australia’s property market is slumping, and the major banks recently confirmed residential mortgage applications had been significantly falling since the Federal Government’s budget in May. AFG’s earnings momentum appears difficult to sustain moving forward.

The valuation should be pricing in rising volume risk, not last year’s growth. We see more downside than upside.

The post Buy, hold, sell: South32, Australian Finance Group, Magellan shares appeared first on The Motley Fool Australia.

More reading

• 5 ASX shares downgraded by Morgans post-results
• Buy, hold, sell: South32, Mineral Resources, BHP shares
• Don’t panic if these 9 ASX 200 shares fall today
• Buy, hold, sell: Boss Energy, Magellan, and NextDC shares
• ASX 200 mining shares outperform in final week of earnings season

Motley Fool contributor Bronwyn Allen has positions in Magellan Financial Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Wildcat Resources Ltd (ASX: WC8) shares are up by more than 120% over the past 12 months, but according to the analyst team at Shaw and Partners that could just be the start of something much bigger.

Shaw and Partners has released a new research note on the company in the wake of Wildcat releasing new drilling results from its Tabba Tabba project in Western Australia.

The broker has a very bullish share price target on the company which I’ll get to shortly.

First let’s look at what the company announced.

Strong drilling results across the board

Wildcat released new drilling results from its Bolt Cutter Central deposit, including both exploration and infill drilling.

The results included intersections such as 8m of 1.5% lithium oxide from a depth of 89m, and 16m at 1.5% from 116m.

Wildcat said Bolt Cutter extended over an area of 2.3km by 0.8km and the mineralisation remains open in most directions.

The company said:

Excellent results from infill drilling continue to demonstrate the strength and continuity of lithium mineralisation at Bolt Cutter Central, with broad, strongly mineralised pegmatites intersected from near surface and extending down dip through the system. Drill targeting and planning of drilling for potential value-add and extensional step-out areas will commence post completion of the maiden resource targeted for delivery in Q4 this year.

The company also reported “excellent” results from metallurgical and infill drilling at the Tabba Tabba deposit, with intersections including 25.1m at 1.2% lithium oxide.

Wildcat said regrading this drill campaign:

Drilling was designed to support ongoing technical studies for the Definitive Feasibility Study (DFS), including the collection of representative material from the Hutt and Chewy pegmatite groups for further metallurgical and resource characterisation. Infill drilling was also undertaken in areas where previous drill rig access constraints had resulted in comparatively wider drill spacing, providing additional geological information and increased confidence in the interpretation of these areas.

The company said that a definitive feasibility study for Tabba Tabba was on track for delivery in the second half of 2026.

Wildcat said it was well-funded, with $37.2 million in cash at the end of June.

Shares looking cheap, broker says

Shaw and Partners said the lithium market was tightening, boding well for Wildcat.

The broker said:

Lithium markets have moved from the oversupplied conditions of the past two years toward renewed tightness as EV demand re-accelerates and high-cost supply continues to be rationalised. Even a short disruption, or even the prospect of a prolonged one, will support spot pricing and reinforce the bullish narrative we have been building around the lithium price over the past 12mths. We see this combination: a tightening global supply picture out of Chile and a high quality, low-cost, expanding WA discovery pipeline at Wildcat, as a bullish setup for WC8 shareholders, and we reiterate our positive stance on lithium equities into the 4Q26 resource catalyst window.

Shaw and Partners has a price target of $1.60 on Wildcat shares compared to 39.5 cents currently.

The post This ASX lithium project developer could rise more than 300%: Broker appeared first on The Motley Fool Australia.

More reading

• Wildcat Resources delivers more high-grade lithium drill results
• Up 109%! 3 reasons this ASX All Ords lithium stock is still a buy today
• Buy, hold, sell: Centuria Industrial REIT, Endeavour, Wildcat Resources shares
• Experts name 3 ASX shares to buy this week

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.